Companies /Industrials

CryoPort Inc

NASDAQ: CYRX Integrated Freight & Logistics
$16.71
▼ $0.64 (−3.71%) today
Markets open · 2:24pm ET

CYRX at a Glance

Valuation
Market cap
$878.8M
Profitability
Revenue (TTM)
$186.5M
Profit margin
-20.1%
EPS (TTM)
$-0.81
Price
52-week range
$8 – $18
Street target
$19.67
Earnings
Next report
Nov 3, 2026

Headquartered in Brentwood, TN Fiscal year ends December NASDAQ: CYRX cryoportinc.com

About Cryoport

Cryoport, Inc. (NASDAQ: CYRX) is a global provider of integrated temperature-controlled supply chain solutions for the life sciences industry, with a particular emphasis on regenerative medicine, including cell and gene therapies. The company serves biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), developers, and researchers. Its platform encompasses the Cryoportal logistics management system, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services (IntegriCell), and cryogenic systems manufactured under the MVE Biological Solutions brand. The company operates through two primary segments: Life Sciences Services (comprising BioLogistics Solutions and BioStorage/BioServices) and Life Sciences Products. As of June 30, 2026, Cryoport supported 779 global clinical trials and 22 commercially approved cell and gene therapies, maintaining operations across the Americas, EMEA, and APAC regions. The company divested its CRYOPDP specialty courier business to DHL Group in June 2025. Updated

CYRX Coverage

Frequently Asked Questions

What does Cryoport do?

Cryoport, Inc. (NASDAQ: CYRX) is a global provider of integrated temperature-controlled supply chain solutions for the life sciences industry, with a particular emphasis on regenerative medicine, including cell and gene therapies.

What is the CYRX stock price target?

The Wall Street consensus 12-month price target for CYRX is $19.67.